menu

New Frontiers in Optimizing Patient Outcomes in Multiple Sclerosis: Strategies for Early Intervention to Address Progression Ind

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

New Frontiers in Optimizing Patient Outcomes in Multiple Sclerosis: Strategies for Early Intervention to Address Progression Independent of Relapse

1.00 credits
60 minutes

CME/CE Broadcast Replay

ReachMD Healthcare Image
Restart
Resume
Choose a format
Take Post-TestSkip straight to the post-test if you have already participated in this activity
Media formats available:
1.00 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Related
Comments
  • Overview

    New strategies for early intervention in multiple sclerosis (MS) are focusing on progression independent of relapse. These strategies include incorporation of high-efficacy disease modifying therapies in the early stages of MS coupled with effective management of treatment-related adverse events. Join Drs. Stephen Kreiger, Tirisham Gyang, and Augusto Miravalle for a lively, case-based exchange that will provide key ideas to take back into the clinic.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.  

    In compliance with EBAC guidelines, all speakers/chairpersons participating in this program have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations. The Organizing Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event are declared to the audience prior to the CME activities. 

    Host: 
    Stephen Krieger, MD, FAAN 
    Professor of Neurology 
    Corinne Goldsmith Dickinson Center for MS 
    Icahn School of Medicine at Mount Sinai 
    New York, NY  

    Dr. Krieger has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months: 
    Consulting Fees: Baim Institute, Biogen, Cycle, EMD Serono, Genentech, Novartis, Octave, Genzyme/Sanofi, and TG Therapeutics  No relevant relationships have been reported at this time. 
    Research: Biogen, BMS, Novartis, Sanofi  

    Faculty: 
    Tirisham Gyang, MD 
    Assistant Professor of Neurology 
    Division Director, Multiple Sclerosis and Neuroimmunology 
    Wexner Medical Center 
    The Ohio State University 
    Columbus, OH 

    Dr. Gyang has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months: 
    Consulting Fees: Alexion, EMD Serono, Genentech, Horizon, Sanofi
     

    Augusto Miravalle, MD, FAAN 
    Chief, Multiple Sclerosis Center 
    Associate Professor of Neurology  
    Department of Neurological Sciences  
    Rush University Medical Center 
    Chicago, IL 

    Dr. Miravalle has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months 
    Consulting Fees: Alexion, BMS, EMD Serono, Genentech, Novartis, TG Therapeutics 

    Reviewers/Content Planners/Authors: 

    • Jennifer Brutsche has nothing to disclose.  
    • Barry Fiedel, PhD, has nothing to disclose. 
    • John Maeglin has nothing to disclose.  
    • Andrea Mathis has nothing to disclose. 
    • Brian P. McDonough, MD, FAAFP, has nothing to disclose.
    • Tim Person has nothing to disclose. 
  • Learning Objectives

    Afteparticipating in this educational activity, participants should be better able to:  

    • Identify early disease progression in patients with MS independent of relapse. 
    • Employ a combination of radiographic and biomarker technologies to help identify early disease progression in patients with MS independent of relapse.     
    • Differentiate the unique features of available HE DMTs in the management of patients with MS. 
    • Formulate new strategies to incorporate HE DMTs earlier in the treatment of patients with MS.  
    • Demonstrate enhanced proficiency in recognizing, assessing, and effectively managing potential AEs associated with use of HE DMTs in patients with MS. 
  • Target Audience

    This activity is designed to meet the educational needs of neurologists, primary care providers, OB-GYNs, nurses, and advanced practice providers who treat patients with multiple sclerosis. 

  • Accreditation and Credit Designation Statements

    In support of improving patient care, this activity has been planned and implemented by Global Learning Collaborative (GLC) and MEDCON International. GLC is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team. 

    Global Learning Collaborative (GLC) designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

    Global Learning Collaborative (GLC) designates this activity for 1.0 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.  

    Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. PAs should claim only the credit commensurate with the extent of their participation in the activity.

    This program is accredited by the European Board for Accreditation of Continuing Education for Health Professionals (EBAC) for 1 hour of external CME credit(s). 

    The Accreditation Council for Continuing Medical Education (ACCME®) and EBAC have recognized each other’s accreditation systems as substantially equivalent. 

    Global Learning Collaborative (GLC) designates this activity for 1.0 contact hours/0.10CEUs of pharmacy contact hours.

    The Universal Activity Number for this program is JA0006235-0000-24-033-H01-P. This learning activity is knowledge-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).

  • Provider(s)/Educational Partner(s)



    AGILE – Academy for Global Interprofessional Learning and Education – designs, develops, and delivers education across a broad spectrum of diseases and clinical conditions. Our mission is to serve as a trusted source of clinical information that helps healthcare professionals improve competence, performance, and patient outcomes. 

  • Commercial Support

    This activity is supported by an independent educational grant from EMD Serono, Inc. EMD Serono, Inc. is the Healthcare business of Merck KGaA, Darmstadt, Germany.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and AGILE. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of AGILE you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site. 

    Reproduction Prohibited 
    Reproduction of this material is not permitted without written permission from the copyright owner. 

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Related
Comments
  • Overview

    New strategies for early intervention in multiple sclerosis (MS) are focusing on progression independent of relapse. These strategies include incorporation of high-efficacy disease modifying therapies in the early stages of MS coupled with effective management of treatment-related adverse events. Join Drs. Stephen Kreiger, Tirisham Gyang, and Augusto Miravalle for a lively, case-based exchange that will provide key ideas to take back into the clinic.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.  

    In compliance with EBAC guidelines, all speakers/chairpersons participating in this program have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations. The Organizing Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event are declared to the audience prior to the CME activities. 

    Host: 
    Stephen Krieger, MD, FAAN 
    Professor of Neurology 
    Corinne Goldsmith Dickinson Center for MS 
    Icahn School of Medicine at Mount Sinai 
    New York, NY  

    Dr. Krieger has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months: 
    Consulting Fees: Baim Institute, Biogen, Cycle, EMD Serono, Genentech, Novartis, Octave, Genzyme/Sanofi, and TG Therapeutics  No relevant relationships have been reported at this time. 
    Research: Biogen, BMS, Novartis, Sanofi  

    Faculty: 
    Tirisham Gyang, MD 
    Assistant Professor of Neurology 
    Division Director, Multiple Sclerosis and Neuroimmunology 
    Wexner Medical Center 
    The Ohio State University 
    Columbus, OH 

    Dr. Gyang has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months: 
    Consulting Fees: Alexion, EMD Serono, Genentech, Horizon, Sanofi
     

    Augusto Miravalle, MD, FAAN 
    Chief, Multiple Sclerosis Center 
    Associate Professor of Neurology  
    Department of Neurological Sciences  
    Rush University Medical Center 
    Chicago, IL 

    Dr. Miravalle has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months 
    Consulting Fees: Alexion, BMS, EMD Serono, Genentech, Novartis, TG Therapeutics 

    Reviewers/Content Planners/Authors: 

    • Jennifer Brutsche has nothing to disclose.  
    • Barry Fiedel, PhD, has nothing to disclose. 
    • John Maeglin has nothing to disclose.  
    • Andrea Mathis has nothing to disclose. 
    • Brian P. McDonough, MD, FAAFP, has nothing to disclose.
    • Tim Person has nothing to disclose. 
  • Learning Objectives

    Afteparticipating in this educational activity, participants should be better able to:  

    • Identify early disease progression in patients with MS independent of relapse. 
    • Employ a combination of radiographic and biomarker technologies to help identify early disease progression in patients with MS independent of relapse.     
    • Differentiate the unique features of available HE DMTs in the management of patients with MS. 
    • Formulate new strategies to incorporate HE DMTs earlier in the treatment of patients with MS.  
    • Demonstrate enhanced proficiency in recognizing, assessing, and effectively managing potential AEs associated with use of HE DMTs in patients with MS. 
  • Target Audience

    This activity is designed to meet the educational needs of neurologists, primary care providers, OB-GYNs, nurses, and advanced practice providers who treat patients with multiple sclerosis. 

  • Accreditation and Credit Designation Statements

    In support of improving patient care, this activity has been planned and implemented by Global Learning Collaborative (GLC) and MEDCON International. GLC is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team. 

    Global Learning Collaborative (GLC) designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

    Global Learning Collaborative (GLC) designates this activity for 1.0 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.  

    Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. PAs should claim only the credit commensurate with the extent of their participation in the activity.

    This program is accredited by the European Board for Accreditation of Continuing Education for Health Professionals (EBAC) for 1 hour of external CME credit(s). 

    The Accreditation Council for Continuing Medical Education (ACCME®) and EBAC have recognized each other’s accreditation systems as substantially equivalent. 

    Global Learning Collaborative (GLC) designates this activity for 1.0 contact hours/0.10CEUs of pharmacy contact hours.

    The Universal Activity Number for this program is JA0006235-0000-24-033-H01-P. This learning activity is knowledge-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).

  • Provider(s)/Educational Partner(s)



    AGILE – Academy for Global Interprofessional Learning and Education – designs, develops, and delivers education across a broad spectrum of diseases and clinical conditions. Our mission is to serve as a trusted source of clinical information that helps healthcare professionals improve competence, performance, and patient outcomes. 

  • Commercial Support

    This activity is supported by an independent educational grant from EMD Serono, Inc. EMD Serono, Inc. is the Healthcare business of Merck KGaA, Darmstadt, Germany.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and AGILE. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of AGILE you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site. 

    Reproduction Prohibited 
    Reproduction of this material is not permitted without written permission from the copyright owner. 

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule23 Apr 2024